Sorrento plans phase II trial for COVID-19 treatment

By The Science Advisory Board staff writers

July 20, 2020 -- Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.

The tyrosine kinase inhibitor, licensed from Acea Therapuetics, is a potent immunomodulator that inhibits pro-inflammatory cytokine production, including interleukin 1 beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF alpha). These cytokines have been associated with cytokine storms and COVID-19 progression with poor outcomes in patients with acute respiratory distress syndrome (ARDS).

The phase II, double-blind, randomized clinical study (NCT04440007) will be initially conducted in the U.S.

Abivertinib has previously been studied in over 600 patients with various oncologic indications.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.